The severity levels of hemophilia are determined by the level of residual/remaining clotting factor (factor VIII or factor IX) activity in the patient’s blood, which is denoted by the percentage of factor activity in the blood (or international units per ml of blood – IU/ml). According to the World Federation of Hemophilia,…
Search results for:
Hemophilia severity is classified as mild, moderate, or severe based on residual clotting factor activity. Jivi is an approved extended half-life (EHL) therapy for hemophilia A, preventing and treating bleeds by providing a lab-made factor VIII. EHL products offer less frequent injections and improved adherence. Support groups and online communities provide resources for managing hemophilia A.
AI-generated summaries are for informational use only, based on content from multiple pages. They may not reflect full context. For complete details, see the original sources. Consult a qualified healthcare professional for medical advice.
Labor and delivery in women with hemophilia Planning for childbirth depends on the needs of the mother and the child affected by hemophilia. Levels of clotting factors should be measured in the last trimester of pregnancy, since it is difficult to measure during labor. If levels are low, treatment may…
BAY 94-9027, developed by Bayer, is an investigational treatment for severe hemophilia A. It is a PEGylated molecule of recombinant factor VIII in which the B-domain, a region within the factor, is deleted. The therapy is produced using a baby hamster kidney cell line (BHK-21), and has…
The recommended treatment regimen for patients with severe hemophilia to prevent bleeding episodes is to replace the deficient clotting factor. However, currently available replacement clotting factors are limited by their relatively short half-lives and require intravenous injections up to three times a week to maintain protective levels. This can have…
Hemophilia A is a rare genetic disorder that affects the blood’s ability to clot properly. It is the most common form of hemophilia, responsible for 80% of all cases.
Social Clips
7 Recommended Books to Learn More About Hemophilia
Hemophilia is a genetic disorder that prevents blood clotting. Most common in men, there are two main types of hemophilia: hemophilia A and B. Below is a curated list of recommended reads for family members, friends and carers of patients with hemophilia, with help from Good Reads and Alibris.
In the U.S., hemophilia A is estimated to affect one in every 5,000 male births, hemophilia B one in 25,000 male births, and hemophilia C one in every 100,000 people (males and females). Hemophilia A is thus four times more common than hemophilia B, and about 10 times more common than…
Hemophilia is a rare disorder in which a person’s blood is not able to clot properly, resulting in unusually easy and prolonged bleeding.
There are several types of hemophilia, a rare bleeding disorder wherein the blood fails to clot properly. Hemophilia A and B are the most common types, while hemophilia C is comparatively rare.